Schizophrenia & Psychosis
Top Stories
-
Source:
Psychiatric Times
“Our findings open the door for the development of treatments to target specific symptoms of psychosis depending on an individual subject’s symptom profile," says Guillermo Horga, MD, PhD
-
Source:
Psychiatric Times
Dr. Joshua Kantrowitz discusses a recent trial of CVN058, a drug that may reduce cognitive impairments in individuals with schizophrenia.
-
Columbia researchers have found a potential neurobiological mechanism for hallucinations and delusions that fits within the hierarchical model of psychosis and can explain their clinical presentation
-
Dr. Ragy Girgis speaks about the benefits of treating those with psychosis early in their illness.
Latest News
-
Source:
Columbia Journalism Review
Dr. Stephanie Le Melle speaks with the editor and publisher of CJR about how to report on police violence against Black sufferers of serious mental illness.
-
"Teletherapy and virtual medication management alone may not adequately address the needs of some of the populations we serve," writes Dr. Angela Coombs.
-
Source:
Psychiatric Times
“The emergence of COVID-19 has forced health systems to transition rapidly to telehealth, while psychiatric research has ground to a halt,” writes Dr. Ragy Girgis and his co-authors.
-
Source:
Psychiatric Times
The results "indicate that KarXT, if approved, could represent a game-changing therapeutic advance in the treatment of patients with schizophrenia,” noted Dr. Jeffrey Lieberman.
-
The study "contributes to efforts that may one day redefine the diagnostic system in psychiatry, which may have practical clinical implications," commented Dr. Tiffany Herlands.
-
“For some people, this illness is highly disabling, but there’s a significant number of people who have this illness who are able to live very fulfilling lives,” said Dr. Lisa Dixon.
-
“Ultimately we want to identify people who are at risk before onset and try to prevent the development of psychosis,” says Dr. Lisa Dixon.
-
In an accompanying editorial, Dr. Joshua T. Kantrowitz explained how the future role of lumateperone could be crucial in treating schizophrenia patients.
-
“The efficacy and safety profile of CAPLYTA approved by the FDA, offers healthcare providers an important new option for treating people living with schizophrenia,” said Dr. Jeffrey A. Lieberman.
-
Drs. Drew Ramsey and Lisa B. Dixon discuss first-episode psychosis and effective interventions.
Pages
